Benchmark Reiterates Speculative Buy on Hoth Therapeutics, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Bruce Jackson reiterates a Speculative Buy rating on Hoth Therapeutics (NASDAQ:HOTH) and maintains a $5 price target.
June 20, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson reiterates a Speculative Buy rating on Hoth Therapeutics and maintains a $5 price target.
The Speculative Buy rating and maintained $5 price target by Benchmark analyst Bruce Jackson indicates a positive outlook for Hoth Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100